All News
Don’t be ‘ticked’: TYK2 is not a JAK!
Recently the FDA approved deucravacitinib, a highly selective TYK2 inhibitor for psoriasis. Trials are positive in psoriatic arthritis and a phase II study in SLE. What about the effects? Presentations from the ACR22 meeting may provide answers.
Read Article
#ACR22 Abstr#0127. Cross-sectional study of 59 patients with #SAPHO and Chronic Nonbacterial Osteomyelitis showed that patients had high level of pain and fatigue and low function. Important to assess for these and could be a treatment target @RheumNow https://t.co/451KrlJWZF
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
mTORC1 may be driver of inflammation that connects the pathogenesis of sJIA and MAS as seen in mouse models. Further evaluation needs to be determined in humans, but interesting nonetheless. Abs 0004 #ACR22 @RheumNow https://t.co/RFokZqFQZp https://t.co/E7yxCPDGCd
Dr. Rachel Tate uptoTate ( View Tweet)
🪞MIRROR RCT🪞
💊MTX ⬆️ response of Pegloticase in resistant gout pts (60% vs PBO 30.8%)
🦶Tophus resolution wk 52 >24 (cont. benefit💪🏻)
🧪⬇️ drug Ab with MTX
✅ No new IRs
Abst#0001 #ACR22 @RheumNow #plenary https://t.co/8lPKQ0VGqC
Patricia Harkins DrTrishHarkins ( View Tweet)
Excellent start to the first plenary session!
MIRROR study - MTX coadministration with pegloticase for gout treatment
- doubling of efficacy and 7x decrease in infusion reactions
- less anti-PEG abs
@RheumNow #ACR22 Abs#0001 https://t.co/V1HIYypmpO
Robert B Chao, MD doctorRBC ( View Tweet)
2022 IIM-assoc'd CA screening key takeaways
Most common CA: lung, ovarian, colorectal, lymphoma, breast, & naso-pharyngeal
High risk: DM, +anti-TIF1 gamma, +antiNXP2, >40 at IIM dx, severe/active dz, cutaneous necrosis, dysphagia
Abs 0002 #ACR22 @RheumNow https://t.co/BhF1jJa8Oz https://t.co/oLVTLG34ck
Dr. Rachel Tate uptoTate ( View Tweet)
So good to be back in the plenary hall. It’s on #ACR22 @RheumNow https://t.co/0ppQy5CA3m
David Liew drdavidliew ( View Tweet)
Best Overall! by Dr. Lauren Harper #ACR22 Image Competition @rheumnow https://t.co/D3bKJTx6ir
TheDaoIndex KDAO2011 ( View Tweet)
Keynote lecture from Abraham Varghese at #ACR22 @RheumNow Opening Session Physicians and Patients
◦ Physical examination is meaningful and cannot be replaced by technology
◦ Don’t treat the EHR, treat the patient
◦ Acknowledge how much goes into patient care by our nurses https://t.co/piV0O8O7Hw
Dr. Antoni Chan synovialjoints ( View Tweet)
@MayoClinic data for bari in relapsing GCA caused waves at #ACR21
Spanish data looking at real-world practice: slightly longer, slower GCA, but equally encouraging outcomes
waiting for SELECT-GCA with interest! @EBRheum
ABST0464 #ACR22 @RheumNow https://t.co/pVRPXAohhc https://t.co/FgNNfPSWk3
David Liew drdavidliew ( View Tweet)
Ab0349 #ACR22 BEL vs AZA ifn risks in non-renal SLE
BEL: lower risk of severe ifn (HR 0.81) and hospitalization for ifn (HR 0.73) through 5 yrs
Challenge to interpret data as 56% of patients were on glucocorticoids and other anti-rheumatic meds
@RheumNow https://t.co/a0tNFn5Wqr
Eric Dein ericdeinmd ( View Tweet)
⬆️ correlation between BASDAI + ASQoL in 🙋♂️ vs 🙋♀️
What does this mean?
❓low disease activity in 🙋♀️ resulting in more marked ⬇️ in QoL❓
OR
❓Is there a need for gender stratified tools of disease activity❓
Abst#0406
#ACR22 @RheumNow @Sineadm15
Patricia Harkins DrTrishHarkins ( View Tweet)
A #myositis discussion will not be complete without a slide on myositis antibodies - @JuliePaikMD
Great review slide for trainees!
#ACR22 @Rheumnow #RheumTwitter @rheumarhyme @PhRheumaJr @doktora_ging https://t.co/e6cB344vH8
sheila RHEUMarampa ( View Tweet)
MIRROR results showed 12-month safety/efficacy support MTX co-therapy w/ pegloticase. No IRs after 6mo of tx and increased resolution of tophi at wk 52. I use MTX in my gout pts on Pegloticase. Are you #rheumtwitter? Abs 0001 #ACR22 @RheumNow https://t.co/FLwOmAYrS4
Dr. Rachel Tate uptoTate ( View Tweet)
🔸DM pts who are anti-TIF-1 Ab+ have higher risk of malignancy
🔸Ovarian cancer - most common
Really important to do cancer screening in #dermatomyositis
#ACR22 @RheumNow https://t.co/jErqcR0Gyr
sheila RHEUMarampa ( View Tweet)
Study of IV tocilizumab for GCA that led to FDA approval of intravenous TCZ this year (2/2022) -one of Dr. C Langford's pick for #YearinReview
@rheumnow #ACR22 https://t.co/luxDDluddM
TheDaoIndex KDAO2011 ( View Tweet)
Is it the medication or behaviour that increases mortality? #SLICC grp showed in #SLE severe non-adherence to #HCQ in Yr 1 of #lupus = 3 poor outcomes -more 1 flares, 2 damage, 3 5yr-death. Surrogate of other poor health behaviours and/or HCQ? abst#0343 #ACR22 #ACRBest @RheumNow https://t.co/tTRdyti0sf
Janet Pope Janetbirdope ( View Tweet)
OPAL dataset 🇦🇺: 55000+ RA pts, 1/10 first line JAKi. Persistence > if 1st line,< x2 if 3rd line.
1/2 switch JAKi->TNFi
1/3 switch JAKi ->JAKi
Why high proportion of JAKi cycling, when AE reason for switch low?
https://t.co/APdWW7fzJE
Abst #0274 #ACR22 @Rheumnow @ClaireDeakin10 https://t.co/3xM3lQO1wI
Aurelie Najm AurelieRheumo ( View Tweet)
Ab#0348 #ACR22: Meta-analysis of Belimumab for CLE w or w/o SLE
13 studies included: 70% with low risk of bias
BEL improved clinical response at W52 vs non-users OR 1.44
Decrease risk of severe cutaneous flare OR 0.51
Most studies against placebo group
@RheumNow https://t.co/2bSwNKRHZZ
Eric Dein ericdeinmd ( View Tweet)
TCZ in GCA: what does it mean for diabetes?
post-hoc GiACTA:
HbA1c obvs better with TCZ (PNL dosing)
but then: even after adjusting for PNL dose, apparent benefit
Is there protective effect?
Interesting observation worth investigating
ABST0461 @MGHrheumatology #ACR22 @RheumNow https://t.co/CF1as5y7Yy
David Liew drdavidliew ( View Tweet)